CSL said it expects Seqirus to record a loss in second half of fiscal 2024 due to lower seasonal demand for immunisation against influenza. — Bloomberg
SYDNEY: Australia’s CSL Ltd forecast weaker outlook for its influenza vaccine making division, Seqirus, and newly acquired anaemia therapy unit, Vifor, sending its shares down to their lowest levels in nearly two months.
CSL’s shares extended losses from Monday when a rare failure for the Phase III trial of its “heart attack” drug CSL112 pushed the company’s stock to the lowest spot in the Australian benchmark index.
